论文部分内容阅读
1例38岁女性患者,因红皮病、急性肾衰竭入院。入院时检测示:WBC 25.03×109/L,RBC 4.26×1012/L,Hb 130 g/L,PLT279×109/L。入院第7天,为控制感染给予利奈唑胺600 mg静脉滴注,2次/d。第17天停用利奈唑胺,改为替考拉宁400mg静滴,1次/48 h。第19天查PLT为25×109/L。第20天停用替考拉宁,改为利奈唑胺600 mg,2次/d。查PLT为37×109/L。第22天停用利奈唑胺,改为替考拉宁400 mg静滴,并输入新鲜血浆和血小板各200 ml。入院第35天患者PLT为101×109/L。
A 38-year-old female patient admitted to hospital with erythroderma and acute renal failure. At admission examination showed: WBC 25.03 × 109 / L, RBC 4.26 × 1012 / L, Hb 130 g / L, PLT279 × 109 / L. On the 7th day of admission, linezolid 600 mg was given intravenously for the control of infection twice daily. Dayline delineation of linezolid, to teicoplanin 400mg intravenous infusion, 1 time / 48 h. The first nine days to check PLT 25 × 109 / L. Teicoplanin was discontinued on day 20 and changed to linezolid 600 mg twice daily. Check PLT 37 × 109 / L. On the 22nd day linezolid was discontinued, replaced with teicoplanin 400 mg intravenous infusion, and the importation of fresh plasma and platelets of 200 ml each. On the 35th day of admission, the PLT was 101 × 109 / L.